David Levitz, Martin Gutierrez, Ira Seth Winer, Matthew Reilley, Linda R. Duska, Vivek Subbiah, Debra L. Richardson, Chet Bohac, MICHAEL CHIARELLA, Carlos Naranjo, Jitendra Kanodia, Jacky Woo, Nicole Nevadunsky. "A phase 1, first-in-human, dose escalation and expansion study to evaluate the safety and tolerability of XmAb541 (claudin-6 x CD3) T-cell engaging bispecific antibody in subjects with germ cell tumors and other advanced solid tumors.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.5_suppl.tps652